1PM7 image
Deposition Date 2003-06-10
Release Date 2003-12-09
Last Version Date 2024-02-14
Entry Detail
PDB ID:
1PM7
Keywords:
Title:
RmlC (dTDP-6-DEOXY-D-XYLO-4-HEXULOSE 3,5-EPIMERASE)STRUCTURE FROM MYCOBACTERIUM TUBERCULOSIS AND INHIBITOR DESIGN. THE APO STRUCTURE.
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.28
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 32
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:RFBC
Chain IDs:A, B
Chain Length:202
Number of Molecules:2
Biological Source:Mycobacterium tuberculosis
Primary Citation
Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis.
Bioorg.Med.Chem.Lett. 13 3227 3230 (2003)
PMID: 12951098 DOI: 10.1016/S0960-894X(03)00673-5

Abstact

The emergence of multi-drug resistant tuberculosis, coupled with the increasing overlap of the AIDS and tuberculosis pandemics has brought tuberculosis to the forefront as a major worldwide health concern. In an attempt to find new inhibitors of the enzymes in the essential rhamnose biosynthetic pathway, a virtual library of 2,3,5 trisubstituted-4-thiazolidinones was created. These compounds were then docked into the active site cavity of 6'hydroxyl; dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (RmlC) from Mycobacterium tuberculosis. The resulting docked conformations were consensus scored and the top 5% were slated for synthesis. Thus far, 94 compounds have been successfully synthesized and initially tested. Of those, 30 (32%) have > or =50% inhibitory activity (at 20 microM) in the coupled rhamnose synthetic assay with seven of the 30 also having modest activity against whole-cell M. tuberculosis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures